Clinical Study

Effect of HSV-2 Suppressive Therapy on Genital Tract HIV-1 RNA Shedding among Women on HAART: A Pilot Randomized Controlled Trial

Table 3

Primary and secondary outcomes analysis.

Acyclovir versus controlOR (95% CI) value

GT HIV-1 RNA
 Detection1.23 (0.47, 3.20)0.67
 Quantity0.92 (0.28, 3.06)0.90
 Detection when PVL is undetectable0.42 (0.17, 1.06)0.07
 Quantity when PVL is undetectable0.34 (0.11, 1.05)0.06
HSV DNA
 Detection0.38 (0.15, 0.99)<0.05
Plasma HIV-1 RNA
 Detection1.93 (0.66, 5.68)0.23
 Quantity3.33 (0.61, 16.67)0.17
Adherence
 Three-day nonadherence to HAART0.93 (0.47, 1.86)0.84
 Two-week nonadherence to HAART1.30 (0.59, 2.87)0.51

NOTE. GT, Genital Tract; RNA, ribonucleic acid; PVL, plasma viral load; HSV, herpes simplex virus; DNA, deoxyribonucleic acid; HAART, highly active antiretroviral therapy.